SIB-RT Combined With CAPOX and PD-1 for High-Risk Rectal Cancer

SIB-RT Combined With CAPOX and PD-1 for High-Risk Rectal Cancer is a phase 2, interventional study registered as NCT07297030 by Sun Yat-sen University, with a registry enrolment figure of 37 participants, started 2025-12-20 and due to reach its primary completion in 2026-05-31. Interventions recorded: SIB-SCRT; CAPOX; Immunotherapy. Conditions listed: Rectal Cancer. Primary outcome: The Complete Response (CR) rate. Colorectal eligibility wording from the registry: "* Histologically confirmed diagnosis of rectal adenocarcinoma". Sites: China. No results are recorded here; the registry entry is the source.